Crescenzo D'alterio

List of Publications by Year
in descending order

34 papers	1,302 citations	361413 20 h-index	377865 34 g-index
35 all docs	35 docs citations	35 times ranked	2399 citing authors

#	Article	IF	Citations
1	Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Seminars in Cancer Biology, 2020, 60, 351-361.	9.6	122
2	Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer. Scientific Reports, 2015, 5, 10357.	3.3	87
3	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. Journal of Translational Medicine, 2017, 15, 46.	4.4	85
4	Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle, 2010, 9, 4492-4500.	2.6	77
5	Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. PLoS ONE, 2013, 8, e74548.	2.5	76
6	A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion. Cancer Letters, 2016, 370, 100-107.	7.2	74
7	Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. Journal of Experimental and Clinical Cancer Research, 2019, 38, 432.	8.6	74
8	Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer. Current Cancer Drug Targets, 2010, 10, 772-781.	1.6	73
9	Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. Cancer Immunology Research, 2016, 4, 366-374.	3.4	61
10	Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget, 2017, 8, 77110-77120.	1.8	59
11	Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunology, Immunotherapy, 2012, 61, 1713-1720.	4.2	55
12	Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget, 2015, 6, 8261-8270.	1.8	54
13	CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. Cellular and Molecular Immunology, 2015, 12, 474-482.	10.5	39
14	CXCR4â€“CXCL12â€“CXCR7, TLR2â€“TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. OncoImmunology, 2016, 5, e1254313.	4.6	36
15	A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. International Journal of Cancer, 2014, 135, 379-390.	5.1	32
16	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. International Journal of Molecular Sciences, 2016, 17, 790.	4.1	32
17	High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer. Current Cancer Drug Targets, 2012, 12, 693-702.	1.6	28
18	CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. Frontiers in Bioscience - Elite, 2010, E2, 13-21.	1.8	27

#	Article	IF	Citations
19	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget, 2016, 7, 18865-18875.	1.8	26
20	Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. Journal of Medicinal Chemistry, 2016, 59, 8369-8380.	6.4	26
21	Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110114.	3.2	21
22	A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors. Scientific Reports, 2017, 7, 2554.	3.3	17
23	New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer. Cancers, 2020, 12, 1952.	3.7	16
24	CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. Nanoscale, 2016, 8, 7562-7571.	5.6	15
25	High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid Carcinoma. Thyroid, 2016, 26, 552-558.	4.5	12
26	A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration. Cell Cycle, 2009, 8, 1228-1237.	2.6	11
27	Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. Journal of Experimental and Clinical Cancer Research, 2018, 37, 297.	8.6	11
28	Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. BMC Cancer, 2019, 19, 899.	2.6	10
29	CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells. Cell Death and Disease, 2019, 10, 562.	6.3	9
30	New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM. Vaccines, 2020, 8, 164.	4.4	9
31	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. Molecular Therapy, 2021, 29, 2963-2978.	8.2	9
32	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. Journal of Medicinal Chemistry, 2021, 64, 3449-3461.	6.4	8
33	Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592198922.	3.2	7
34	Protein gene product 9.5 is diagnostically helpful in delineating high-grade renal cell cancer involving the renal medullary/sinus region from invasive urothelial cell carcinoma of the renal pelvis. Human Pathology, 2013, 44, 712-717.	2.0	4